Led · Equity · Mar 2024

Braingaze develops diagnostic and therapeutic products that combine patented biomarkers of ocular micromovements, casual video games, and deep-learning algorithms. Its diagnostic solutions aim to deliver cutting-edge accuracy and objectivity for conditions such as ADHD, Alzheimer’s disease, and autism spectrum disorder. The company’s therapeutic offering, including BGaze Therapy — an eye-movement attention-training game — has been tested in clinics and shown promising improvements in cognitive function beyond behavioral training, reportedly mimicking pharmacological effects without side effects. Braingaze’s ADHD diagnostic tools have been used in clinical practice in Spain by pioneering physicians in Madrid and Barcelona. The company plans to use the new funding to accelerate clinical and commercial development, launch clinical solutions, and expand access to consumers via mobile platforms. CEO Laszlo Bax said the team is focused on executing the milestones ahead and growing multi-market business traction. Braingaze develops next-generation eye-tracking software that predicts and identifies personal behaviour for clinical and commercial applications. The company is building several applications, including tools for diagnosing ADHD, analysing consumer preference, and aiding video game navigation. New funding will be used primarily for R&D, product development, patent expansion, regulatory compliance, and to develop a clinical trial programme in Europe and the US. Braingaze recently secured €336K of public and private capital in its first pre-seed round. The seven-person team has moved into larger offices within the Tecnocampus Mataró incubator near Barcelona. Founders Laszlo Bax and Hans Super also increased their investment at the same valuation offered to new investors.

Participated · Seed · Nov 2020

knok, founded in 2015 by José Bastos and Dr. João Magalhães, offers a single platform for secure video consultations and supporting tools for remote patient monitoring using artificial intelligence. The platform enables patients to share symptoms and medical information and allows clinicians to conduct integrated video consults across more than nine medical specialties. knok says its technology is based on data gathered from hundreds of thousands of video consultations and has been used in more than 160,000 consultations. The company is active across 12 countries and serves roughly 30 clients (hospitals, clinics and insurers) with over 3,100 active doctors. The new financing will be used to develop fully integrated telemedicine solutions that leverage 5G to improve access, reliability and collaboration, particularly for remote locations. Management plans to accelerate national and international expansion, strengthening presence in Spain, Brazil and other Latin American markets while opening new markets such as India, the UK and Italy. knokcare is a Porto-based health startup founded in 2015 that offers an application to facilitate access to primary care physicians via video consultations. The platform includes features for multidisciplinary and group consultations, enabling a doctor, patient and a family member or caregiver to participate and share information. knokcare serves more than 1.2 million patients worldwide, with presence in countries such as Brazil, South Africa and Angola, and has partnerships with Europ Assistance, AdvanceCare and Medicare, Grupo Lusíadas Saúde and NOS. It is also an accredited service provider to the UK’s NHS. The team is preparing to enter the Indian and Italian markets and is developing a specific solution for nursing homes in response to pandemic challenges. Recent fundraising will be used to strengthen the sales team and accelerate market entry with differentiated products and services. knok operates an "Uber-style" private healthcare platform enabling patients to access on-demand, in-person medical support at their chosen location. The platform charges €49 for general practice and specialist appointments in Portugal. Launched in December 2015, knok reported an average weekly growth rate of 15% over the past 10 months. The company positions itself on efficiency and affordability while aiming to provide personalized, high-quality care and additional compensation opportunities for junior doctors. knok plans to use the new funding to expand services within Portugal and into other countries. Early traction and the platform's pricing suggest accelerating demand for its on‑demand medical services.

Led · Equity · Aug 2020

Log my Care provides a mobile-first software platform that enables carers to record patient notes, access medical records and receive prompts and reminders. The app typically saves carers up to an hour per shift and allows creation of personalised care plans in about a third of the time. The platform is designed to improve efficiency, care quality and oversight for care providers. It supports over 1,300 care providers and around 20,000 patients, and is particularly popular with independent providers and those in the learning disability sector. The company plans to use the new funding to consolidate its position in the learning disability sector and expand its presence in home care. Founded in 2017 by Sam Hussain and Adam Hurst and based in London, Log my Care has raised a further £3M from Mercia Ventures. Log my Care provides a mobile-first platform that enables carers in any setting to replace paperwork, find patient records and save time. The product harnesses data to create personalised care plans and to help organisations improve operations. It is used by over 800 care providers and supports roughly 10,000 people each week. The company reports monthly recurring revenue has increased almost 300% in the past 12 months and headcount has grown from 6 to 24. Management says the new funding will be used to expand operations and broaden the company’s business reach. Log my Care provides a cloud-based care planning software platform that enables care homes to move admin and care planning online. The app is in use across hundreds of care services by thousands of carers, who have recorded nearly 30 million care logs. In response to COVID-19 the company developed a real-time symptom tracking tool and a track-and-trace tool to help monitor and isolate at-risk carers and service users. The core system and the COVID-19 tools are free to use for all registered UK care homes and care agencies; two optional premium modules are available by monthly subscription. The company plans to use the new funding to build more tools to digitalize and streamline social care and to expand its user base to reach thousands of care services. Log my Care is led by founder Sam Hussain and is based in the UK.